1. Quantification of autoantibodies using a luminescent profiling method in autoimmune interstitial lung disease
- Author
-
Peter D. Burbelo, Julio A. Huapaya, Zohreh Khavandgar, Margaret Beach, Iago Pinal-Fernandez, Andrew L. Mammen, John A. Chiorini, Payam Noroozi Farhadi, Frederick W. Miller, Adam Schiffenbauer, Kakali Sarkar, Blake M. Warner, and Lisa G. Rider
- Subjects
interstitial lung disease ,myositis-specific autoantibody ,myositis-associated autoantibody ,idiopathic inflammatory myopathies ,Sjögren’s disease ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Autoantibodies are important for the diagnosis of autoimmune interstitial lung disease (ILD). Standard immunoassays have limitations, including their qualitative nature and/or a narrow dynamic range of detection, hindering the usefulness of autoantibodies as biomarkers of disease activity. Here, the luciferase immunoprecipitation system (LIPS) was evaluated for measuring myositis-specific and other lung-related autoantibodies in 25 subjects with idiopathic inflammatory myopathies (IIM), 26 with Sjögren’s disease (SjD), and 10 healthy volunteers. LIPS detected a broad dynamic range of autoantibodies, to MDA5, Jo-1, PL12, KS, U1-70K, and Ro52, and matched seropositivity status with established immunoassays. Robust anti-MDA5 autoantibodies in four IIM-ILD patients had a median value of 1,134,000 LU (IQR 473,000-2,317,000), which was 500 times higher than in 21 seronegative IIM patients. Markedly elevated anti-Jo-1 autoantibodies in five IIM-ILD patients demonstrated a median value of 1,177,000 LU (IQR: 604,000-2,520,000), which was 1000-fold higher than in seronegative patients. Robust anti-Ro52 and other anti-tRNA-synthetase autoantibodies were detected in a subset of IIM-ILD subjects. In SjD, only anti-U1-70K and KS autoantibodies were identified in ILD patients with a prevalence of 30% and 20%, respectively. In longitudinal samples of five IIM-ILD patients, anti-Jo-1 autoantibody levels paralleled clinical improvement of lung function. LIPS can accurately quantify autoantibody levels as biomarkers for treatment response in patients with autoimmune ILD.
- Published
- 2024
- Full Text
- View/download PDF